- Home
- MCRB
as 07-26-2024 4:00pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 142.0M | IPO Year: | 2015 |
| Target Price: | $5.75 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $5.29 | Next Earning Date: | 08-06-2024 |
| Revenue: | $126,847,000 | Revenue Growth: | 2380.87% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shaff Eric D. | MCRB | CEO and President | May 15 '24 | Sell | $0.94 | 2,435 | $2,288.90 | 140,698 | SEC Form 4 |
| Henn Matthew R. | MCRB | See Remarks | May 15 '24 | Sell | $0.94 | 891 | $837.54 | 65,357 | SEC Form 4 |
| Ege David S. | MCRB | See Remarks | May 15 '24 | Sell | $0.94 | 1,090 | $1,024.60 | 75,734 | SEC Form 4 |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | May 15 '24 | Sell | $0.94 | 843 | $792.42 | 122,390 | SEC Form 4 |
| Young Teresa L. | MCRB | See Remarks | May 15 '24 | Sell | $0.94 | 703 | $660.82 | 17,658 | SEC Form 4 |
| von Moltke Lisa | MCRB | See Remarks | May 14 '24 | Sell | $0.94 | 939 | $882.66 | 19,017 | SEC Form 4 |
| Young Teresa L. | MCRB | See Remarks | Feb 14 '24 | Sell | $1.08 | 3,374 | $3,643.92 | 15,705 | SEC Form 4 |
| Ege David S. | MCRB | See Remarks | Feb 14 '24 | Sell | $1.08 | 5,010 | $5,410.80 | 73,856 | SEC Form 4 |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Feb 14 '24 | Sell | $1.08 | 3,939 | $4,254.12 | 120,577 | SEC Form 4 |
| Henn Matthew R. | MCRB | See Remarks | Feb 14 '24 | Sell | $1.08 | 4,170 | $4,503.60 | 63,436 | SEC Form 4 |
| Arkowitz David | MCRB | Chief Financial Officer | Feb 14 '24 | Sell | $1.08 | 3,939 | $4,254.12 | 182,442 | SEC Form 4 |
| von Moltke Lisa | MCRB | See Remarks | Feb 14 '24 | Sell | $1.08 | 4,400 | $4,752.00 | 16,988 | SEC Form 4 |
| Young Teresa L. | MCRB | See Remarks | Oct 27 '23 | Sell | $1.35 | 2,907 | $3,924.45 | 8,454 | SEC Form 4 |
| Arkowitz David | MCRB | Chief Financial Officer | Oct 27 '23 | Sell | $1.35 | 4,066 | $5,489.10 | 175,756 | SEC Form 4 |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Oct 27 '23 | Sell | $1.35 | 4,156 | $5,610.60 | 113,891 | SEC Form 4 |
| von Moltke Lisa | MCRB | See Remarks | Oct 27 '23 | Sell | $1.35 | 4,232 | $5,713.20 | 9,513 | SEC Form 4 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years
GlobeNewswire
2 months ago
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Seres Therapeutics to Sell Vowst Assets to Nestle Health Science
BioPharma Dive
2 months ago
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
PR Newswire
2 months ago
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
GlobeNewswire
2 months ago
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Insider Monkey
2 months ago
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
MT Newswires
3 months ago
Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.